Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_4
2
40%
Ph phase_2
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Completed2
Withdrawn2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 42 (66.7%)

Trials by Status

unknown120%
completed240%
withdrawn240%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

NCT02940496
completed

Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan

NCT03706222
withdrawnphase_4

A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

NCT03585101
withdrawnphase_4

A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A

NCT03105349
unknown

Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy

NCT03433326

Clinical Trials (5)

Showing 5 of 5 trials
NCT02940496Phase 2

Pembrolizumab (MK-3475) in Hepatocellular Carcinoma

Completed
NCT03706222

Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan

Completed
NCT03585101Phase 4

A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk

Withdrawn
NCT03105349Phase 4

A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A

Withdrawn
NCT03433326

Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5